Introduction
============

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in developed countries[@b1]. Furthermore, a recent study showed that the prevalence of NAFLD was 68.5% in obese, 15.2% in non-obese subjects and 24.6% in total among Japanese[@b2]. NAFLD is strongly associated with insulin resistance[@b3],[@b4]. The rate of newly diagnosed prediabetes was 75% in patients with NAFLD, and 25% in those without NAFLD[@b5]. Furthermore, a recent study reported that NAFLD is a strong and independent risk factor for prediabetes[@b6], and that liver enzymes, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT), were strongly associated with diabetes mellitus (DM) risk[@b7],[@b8]. It has also been reported that fatty liver is a risk factor for impaired fasting glucose (IFG) and type 2 DM in Japanese people[@b9], and NAFLD is a risk factor for type 2 DM in middle-aged men[@b10].

The diagnosis of NAFLD is regarded as clinically problematic because of the invasive character of the gold standard method of liver biopsy. Therefore, previous studies clarified NAFLD by using ultrasound[@b1],[@b2],[@b6],[@b9],[@b10], magnetic resonance spectroscopy[@b5], indices of fatty liver[@b11]--[@b13], or two of these[@b4],[@b14]. Bedogni *et al*.[@b11] introduced the fatty liver index (FLI), which was estimated using multivariate models including several biomarkers. These included body mass index (BMI), waist circumference (WC), triglycerides (TGs) and GGT, measured in specific health check-ups in Japan. Specific health check-ups and guidance were implemented to reduce the number of persons with lifestyle-related diseases including DM, in fiscal year (FY) 2008[@b15]. There are few studies to report that FLI is valuable in identifying type 2 diabetes among Asian populations[@b16].

Furthermore, the FLI was required to monitor patients with prediabetes for identification, quantification and characterization of the population of high-risk individuals targeted for ongoing DM primary prevention efforts[@b17]. Also, it was reported that the prevalence of prediabetes increased significantly in both men and women from the 1980s to the 2000s in a general Japanese population[@b18]. The National Health and Nutrition Survey reported that approximately 9.5 million people were strongly suspected as having DM, and a further 11.0 million people were possible candidates for having DM[@b19]. However, a previous study in Asian populations did not classify prediabetes among subjects without DM[@b16]. Previous studies in Japan did not include subjects with impaired glucose tolerance (IGT) and IFG[@b9],[@b10]; but nevertheless, there were 20.5 million people at high risk of having diabetes. Additionally, a recent study reported that NAFLD was a stronger predictor for prediabetes than metabolic syndromes[@b6].

However, there have been few reports establishing the risk for DM among patients with prediabetes among Asian populations, in which the prevalence of DM has rapidly increased in recent decades with economic development including food supply and dietary patterns, technology transfer, and cultural admixture[@b20]. Therefore, we carried out the present study to evaluate the effect of NAFLD on the progression of DM among these patients.

Methods
=======

Participants
------------

The inclusion and exclusion flowchart is shown in Figure[1](#fig01){ref-type="fig"}. We identified 8,982 insurance beneficiaries aged 40 years or older as of 31 March 2009 who worked for health insurance societies located in Fukuoka and Shizuoka Prefectures (Japan), and who attended specific health check-ups at FY2008. For the present study, we excluded 413 insurance beneficiaries who had not attended specific health check-ups at FY2011. From those, we identified 4,830 insurance beneficiaries who were not drinkers or whose alcohol consumption was less than 19 g per day. After converting hemoglobin A1c (HbA1c), which was in the Japan Diabetes Society (JDS) units to the National Glycohemoglobin Standardization Program (NGSP) units[@b21],[@b22], we excluded 292 insurance beneficiaries whose HbA1c was higher than 6.4% or those taking treatments for DM based on a self-administered questionnaire (insurance beneficiaries with exiting DM), 2,387 insurance beneficiaries without any treatments for DM whose HbA1c was less than 5.7% (insurance beneficiaries with normal glucose tolerance) and 844 of those who did not have their HbA1c values measured or who did not answer questionnaires about treatments for DM (insurance beneficiaries with insufficient data about DM). Thus, we identified 1,307 insurance beneficiaries without treatments for DM whose HbA1c levels ranged 5.7--6.4%. We excluded 141 insurance beneficiaries whose HbA1c, or responses to questionnaires about both drinking behaviors and alcohol consumptions or dietary habits, were not available at FY2011. Furthermore, we excluded 193 insurance beneficiaries who had been diagnosed with stroke, coronary heart disease, chronic kidney disease or anemia based on a self-administered questionnaire. We also excluded six insurance beneficiaries who had been treated for chronic viral hepatitis (International Classification of Diseases 10th revision code: B18) at FY2011, using claims data. Finally, we arrived at 967 insurance beneficiaries as study participants.

![Inclusion and exclusion flowchart. CHD, coronary heart disease; CKD, chronic kidney failure; DM, diabetes mellitus; FY, fiscal year.](jdi0006-0309-f1){#fig01}

The present study was approved by the Kyushu University Institutional Review Board for Clinical Research.

Definition of Variables
-----------------------

The FLI score was used as a surrogate measure for fatty liver. This measure was calculated using the following equation: The FLI varies between 0 and 100. According to a previous study[@b12], FLI \<30 can be used to rule out (sensitivity = 87%; negative likelihood ratio = 0.2) and FLI ≥60 to rule in hepatic steatosis (specificity = 86%; positive likelihood ratio = 4.3). Thus, we defined participants with FLI scores of 60 or higher as having NAFLD, and those with FLI scores of 30 or lower as not having NAFLD. The rest of them were defined as having intermediate FLIs.

Participants with HbA1c values higher than 6.4% or those taking treatments for DM based on self-administered questionnaire at FY2011 were defined as newly diagnosed DM. Ages were categorized into three groups: 40--49, 50--59 and 60 years or older. HbA1c values at baseline were categorized into four groups according to quartiles. Participants whose systolic blood pressure (SBP) was higher than 140 mmHg or whose diastolic blood pressure (DBP) was higher than 90 mmHg, or who used antihypertensive drugs based on self-administered questionnaire were defined as having hypertension. Participants whose low-density cholesterol (LDL-C) was higher than 3.6 mmol/L, or who used cholesterol-lowering drugs based on self-administered questionnaire, were defined as having hypercholesterolemia. Lifestyle habits were respectively categorized based on a self-administered questionnaire. Those who had smoked over the past month and had smoked a total of over 100 cigarettes, or who had smoked over a period of 6 months, were defined as smokers. Those who had habitually exercised for over 30 min twice a week for at least 1 year, or who habitually walked for over 1 h a day, were defined as involved in physical activity. Eating before sleeping, eating fast and prefecture were used as explanatory variables.

Statistical Analysis
--------------------

Participant characteristics were constructed using frequencies and proportions for categorical variables, and using median and interquartile ranges for a continuous variable. Categorical variables were compared between the three groups using Pearson\'s χ^2^-test, and the continuous variable was compared between the three groups using the Kruskal--Wallis test.

Multiple logistic regression analyses were used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) for the incidence of DM. After stratification by sex, we set the incidence of DM as the dependent variable, and age, FLI categories, smoking habits, physical activity, eating before sleeping, eating fast, the presence of hypertension, the presence of hypercholesterolemia and prefecture as independent variables. Statistical analyses were carried out using [pasw]{.smallcaps} version 18.0 (SPSS Inc., Chicago, IL, USA). *P*-values \<0.05 were regarded as statistically significant.

Results
=======

Demographic and physical characteristics of the participants are shown in Table[1](#tbl1){ref-type="table"}. The number of those with NAFLD, intermediate FLIs, and no NAFLD were 499 (51.6%), 281 (29.1%) and 187 (19.3%), respectively. The median age between the groups was significantly different in men (*P* \< 0.001), but not significantly different in women (*P* = 0.588). Biochemical characteristics are shown in Table[2](#tbl2){ref-type="table"}. The median HbA1c was significantly different in both sexes (*P* \< 0.001). Lifestyle habits and comorbidity are shown in Table[3](#tbl3){ref-type="table"}. The prevalence of hypertension and hypercholesterolemia was significantly different in both sexes (*P* \< 0.001, *P* = 0.001 in men; *P* \< 0.001, *P* \< 0.001 in women). The proportion of participants who ate fast was significantly different in men (*P* = 0.017), and the proportion of participants who ate before sleeping was significantly different in women (*P* = 0.010).

###### 

Demographic and physical characteristics of participants according to fatty liver index, by sex

          Total                  FLI           *P*-value                                                     
  ------- ---------------------- ------------- --------------- -------------- -------------- --------------- -----------------------------------------
  Men                                          (*n = *565)     (*n = *209)    (*n = *200)    (*n = *156)     
          Median age (years)     \[IQR\]       49.0 \[8.0\]    50.0 \[8.0\]   50.0 \[8.0\]   47.0 \[8.0\]    \<0.001[†](#tf1-1){ref-type="table-fn"}
          Age (years)            40--49        271 (48.0%)     93 (18.6%)     86 (43.0%)     92 (59.0%)      0.008
          50--59                 258 (45.7%)   97 (19.4%)      102 (51.0%)    59 (37.8%)                     
          ≥60                    36 (6.4%)     19 (3.8%)       12 (6.0%)      5 (3.2%)                       
          Fukuoka Prefecture                   119 (21.1%)     36 (17.2%)     48 (24.0%)     35 (22.4%)      0.216
          Median BMI (kg/m^2^)   \[IQR\]       24.3 \[4.2\]    21.6 \[2.5\]   24.8 \[2.5\]   27.7 \[3.6\]    \<0.001[†](#tf1-1){ref-type="table-fn"}
          Median WC (cm)         \[IQR\]       87.2 \[10.7\]   80.0 \[7.0\]   88.0 \[6.5\]   95.0 \[10.2\]   \<0.001[†](#tf1-1){ref-type="table-fn"}
  Women                                        (*n = 402*)     (*n = 290*)    (*n = 81*)     (*n = 31*)      
          Median age (years)     \[IQR\]       52.0 \[7.0\]    52.0 \[7.0\]   52.0 \[9.0\]   51.0 \[8.0\]    0.588[†](#tf1-1){ref-type="table-fn"}
          Age (years)            40--49        117 (29.1%)     84 (29.0%)     22 (27.2%)     11 (35.5%)      0.788
                                 50--59        247 (61.4%)     180 (62.1%)    49 (60.5%)     18 (58.1%)      
                                 ≥60           38 (9.5%)       26 (9.0%)      10 (12.3%)     2 (6.5%)        
          Fukuoka Prefecture                   105 (26.1%)     75 (25.9%)     23 (28.4%)     7 (22.6%)       0.807
          Median BMI (kg/m^2^)   \[IQR\]       22.7 \[4.9\]    21.6 \[3.4\]   26.0 \[3.4\]   29.8 \[5.5\]    \<0.001[†](#tf1-1){ref-type="table-fn"}
          Median WC (cm)         \[IQR\]       82.0 \[11.7\]   79.3 \[9.4\]   89.5 \[6.5\]   98.2 \[8.7\]    \<0.001[†](#tf1-1){ref-type="table-fn"}
  Total                                        (*n = 967*)     (*n = 499*)    (*n = 281*)    (*n = 187*)     
          Median age (years)     \[IQR\]       51.0 \[8.0\]    51.0 \[8.0\]   51.0 \[7.0\]   48.0 \[9.0\]    \<0.001[†](#tf1-1){ref-type="table-fn"}
          Age (years)            40--49        388 (40.1%)     177 (35.5%)    108 (38.4%)    103 (55.1%)     \<0.001
          50--59                 505 (52.2%)   277 (55.5%)     151 (53.7%)    77 (41.2%)                     
          ≥60                    74 (7.7%)     45 (9.0%)       22 (7.8%)      7 (3.7%)                       
          Sex                    Male          565 (58.4%)     209 (41.9%)    200 (71.2%)    156 (83.4%)     \<0.001
          Female                 402 (41.6%)   290 (58.1%)     81 (28.8%)     31 (16.6%)                     
          Fukuoka Prefecture                   224 (23.2%)     111 (22.2%)    71 (25.3%)     42 (22.5%)      0.610
          Median BMI (kg/m^2^)   \[IQR\]       23.6 \[4.6\]    21.8 \[3.0\]   25.0 \[2.8\]   27.9 \[4.1\]    \<0.001[†](#tf1-1){ref-type="table-fn"}
          Median WC (cm)         \[IQR\]       85.0 \[12.0\]   79.8 \[8.2\]   88.5 \[6.4\]   95.5 \[10.5\]   \<0.001[†](#tf1-1){ref-type="table-fn"}

Compared using the Kruskal--Wallis test. Other comparisons made using the χ^2^ test.

BMI, body mass index; FLI, fatty liver index; IQR, interquartile range; WC, waist circumference.

###### 

Biochemical characteristics of participants according to fatty liver index by sex

          Total                          FLI       *P*-value                                                       
  ------- ------------------------------ --------- --------------- --------------- --------------- --------------- -----------------------------------------
  Men                                              (*n = 565*)     (*n = 209*)     (*n = 200*)     (*n = 156*)     
          Median HbA1c at baseline, %    \[IQR\]   5.9 \[0.3\]     5.8 \[0.3\]     5.9 \[0.3\]     5.9 \[0.2\]     0.274[†](#tf2-1){ref-type="table-fn"}
           Q1                            5.7       154 (27.3%)     61 (29.2%)      56 (28.0%)      37 (23.7%)      0.629
           Q2                            5.8       128 (22.7%)     53 (25.4%)      40 (20.0%)      35 (22.4%)      
           Q3                            5.9       110 (19.5%)     38 (18.2%)      42 (21.0%)      30 (19.2%)      
           Q4                            ≥6.0      173 (30.6%)     57 (27.3%)      62 (31.0%)      54 (34.6%)      
          Median TGs (mmol/L)            \[IQR\]   1.5 \[1.2\]     1.0 \[0.5\]     1.6 \[0.9\]     2.4 \[1.4\]     \<0.001[†](#tf2-1){ref-type="table-fn"}
          Median GGT (U/L)               \[IQR\]   35.0 \[28.0\]   24.0 \[12.0\]   38.0 \[25.0\]   56.5 \[42.0\]   \<0.001[†](#tf2-1){ref-type="table-fn"}
  Women                                            (*n = 402*)     (*n = 290*)     (*n = 81*)      (*n = 31*)      
          Median HbA1c at baseline (%)   \[IQR\]   5.8 \[0.3\]     5.8 \[0.2\]     5.9 \[0.2\]     6.0 \[0.4\]     \<0.001[†](#tf2-1){ref-type="table-fn"}
           Q1                            5.7       120 (29.9%)     97.0 (33.4%)    17.0 (21.0%)    6.0 (19.4%)     0.003
           Q2                            5.8       88 (21.9%)      67.0 (23.1%)    19.0 (23.5%)    2.0 (6.5%)      
           Q3                            5.9       77 (19.2%)      56.0 (19.3%)    15.0 (18.5%)    6.0 (19.4%)     
           Q4                            ≥6.0      117 (29.1%)     70.0 (24.1%)    30.0 (37.0%)    17.0 (54.8%)    
          Median TGs (mmol/L)            \[IQR\]   1.0 \[0.6\]     0.9 \[0.5\]     1.3 \[0.8\]     1.5 \[1.1\]     \<0.001[†](#tf2-1){ref-type="table-fn"}
          Median GGT (U/L)               \[IQR\]   19.0 \[15.0\]   17.0 \[8.0\]    30.0 \[23.0\]   37.0 \[44.0\]   \<0.001[†](#tf2-1){ref-type="table-fn"}
  Total                                            (*n = *967)     (*n = *499)     (*n = *281)     (*n = *187)     
          Median HbA1c at baseline, %    \[IQR\]   5.8 \[0.3\]     5.8 \[0.3\]     5.9 \[0.3\]     5.9 \[0.2\]     \<0.001[†](#tf2-1){ref-type="table-fn"}
           Q1                            5.7       274 (28.3%)     158 (31.7%)     73 (26.0%)      43 (23.0%)      0.028
           Q2                            5.8       216 (22.3%)     120 (24.0%)     59 (21.0%)      37 (19.8%)      
           Q3                            5.9       187 (19.3%)     94 (18.8%)      57 (20.3%)      36 (19.3%)      
           Q4                            ≥6.0      290 (30.0%)     127 (25.5%)     92 (32.7%)      71 (38.0%)      
          Median TGs (mmol/L)            \[IQR\]   1.2 \[1.0\]     0.9 \[0.5\]     2 \[0.9\]       2.3 \[1.4\]     \<0.001[†](#tf2-1){ref-type="table-fn"}
          Median GGT (U/L)               \[IQR\]   28.0 \[27.0\]   20.0 \[13.0\]   35.0 \[25.0\]   53.0 \[44.0\]   \<0.001[†](#tf2-1){ref-type="table-fn"}

Compared using the Kruskal--Wallis test. Other comparisons made using the χ^2^ test.

SI conversion factor: To convert triglycerides to millimoles per liter, multiply by 0.0113.

FLI, fatty liver index; GGT, gamma-glutamyltransferase; IQR, interquartile range; TGs, triglycerides.

###### 

Lifestyle habits and comorbidity of participants according to fatty liver index, by sex

          Total                               FLI       *P*-value                                               
  ------- ----------------------------------- --------- ------------- ------------- ------------- ------------- -----------------------------------------
  Men                                                   (*n = *565)   (*n = *209)   (*n = *200)   (*n = *156)   
          Hypertension                                  160 (28.3%)   38 (18.2%)    68 (34.0%)    54 (34.6%)    \<0.001
          Median SBP (mmHg)                   \[IQR\]   122 \[24\]    116 \[24\]    126 \[24\]    128 \[22\]    \<0.001[†](#tf3-1){ref-type="table-fn"}
          Median DBP (mmHg)                   \[IQR\]   78 \[16\]     72 \[15\]     80 \[18\]     80 \[14\]     \<0.001[†](#tf3-1){ref-type="table-fn"}
          Use of antihypertensive drugs                 53 (9.4%)     13 (6.2%)     25 (12.5%)    15 (9.6%)     0.093
          Hypercholesterolemia                          274 (48.5%)   80 (38.3%)    108 (54.0%)   86 (55.1%)    0.001
          Median LDL-C (mmol/L)               \[IQR\]   3.5 \[1.0\]   3.3 \[0.9\]   3.6 \[0.9\]   3.6 \[1.0\]   0.002[†](#tf3-1){ref-type="table-fn"}
          Use of cholesterol lowering drugs             39 (6.9%)     6 (2.9%)      20 (10.0%)    13 (8.3%)     0.012
          Alcohol consumption \<19 g/day                506 (89.6%)   190 (90.9%)   178 (89.0%)   138 (88.5%)   0.714
          No drinkers                                   320 (56.6%)   122 (58.4%)   104 (52.0%)   94 (60.3%)    0.242
          Smoking                                       251 (44.4%)   98 (46.9%)    80 (40.0%)    73 (46.8%)    0.293
          Physical activities                           174 (30.8%)   63 (30.1%)    65 (32.5%)    46 (29.5%)    0.803
          Eating fast                                   230 (40.7%)   71 (34.0%)    83 (41.5%)    76 (48.7%)    0.017
          Eating before sleeping                        213 (37.7%)   80 (38.3%)    69 (34.5%)    64 (41.0%)    0.441
  Women                                                 (*n = *402)   (*n = *290)   (*n = *81)    (*n = *31)    
          Hypertension                                  85 (21%)      49 (16.9%)    21 (25.9%)    15 (48.4%)    \<0.001
          Median SBP (mmHg)                   \[IQR\]   120 \[25\]    117 \[24\]    125 \[22\]    130 \[26\]    \<0.001[†](#tf3-1){ref-type="table-fn"}
          Median DBP (mmHg)                   \[IQR\]   74 \[12\]     71 \[16\]     79 \[14\]     80 \[18\]     \<0.001[†](#tf3-1){ref-type="table-fn"}
          Use of antihypertensive drugs                 43 (10.7%)    21 (7.2%)     13 (16.0%)    9 (29.0%)     \<0.001
          Hypercholesterolemia                          200 (49.8%)   123 (42.4%)   54 (66.7%)    23 (74.2%)    \<0.001
          Median LDL-C (mmol/L)               \[IQR\]   3.5 \[1.1\]   3.4 \[1.1\]   3.8 \[1.1\]   3.7 \[1.3\]   0.001[†](#tf3-1){ref-type="table-fn"}
          Use of cholesterol lowering drugs             41 (10.2%)    24 (8.3%)     11 (13.6%)    6 (19.4%)     0.081
          Alcohol consumption \<19 g /day               363 (90.3%)   269 (92.8%)   68 (84.0%)    26 (83.9%)    0.027
          No drinkers                                   294 (73.1%)   204 (70.3%)   64 (79.0%)    26 (83.9%)    0.111
          Smoking                                       24 (6.0%)     18 (6.2%)     5 (6.2%)      1 (3.2%)      0.798
          Physical activities                           106 (26.4%)   78 (26.9%)    21 (25.9%)    7 (22.6%)     0.870
          Eating fast                                   136 (33.8%)   91 (31.4%)    33 (40.7%)    12 (38.7%)    0.242
          Eating before sleeping                        114 (28.4%)   70 (24.1%)    31 (38.3%)    13 (41.9%)    0.010
  Total                                                 (*n* = 967)   (*n* = 499)   (*n* = 281)   (*n* = 187)   
          Hypertension                                  245 (25.3%)   87 (17.4%)    89 (31.7%)    69 (36.9%)    \<0.001
          Median SBP (mmHg)                   \[IQR\]   122 \[24\]    117 \[22\]    126 \[24\]    128 \[20\]    \<0.001[†](#tf3-1){ref-type="table-fn"}
          Median DBP (mmHg)                   \[IQR\]   76 \[16\]     72 \[14\]     79 \[16\]     80 \[14\]     \<0.001[†](#tf3-1){ref-type="table-fn"}
          Use of antihypertensive drugs                 96 (9.9%)     34 (6.8%)     38 (13.5%)    24 (12.8%)    0.004
          Hypercholesterolemia                          474 (49.0%)   203 (40.7%)   162 (57.7%)   109 (58.3%)   \<0.001
          Median LDL-C (mmol/L)               \[IQR\]   3.5 \[1.0\]   3.3 \[1.0\]   3.6 \[0.9\]   3.6 \[1.0\]   \<0.001[†](#tf3-1){ref-type="table-fn"}
          Use of cholesterol lowering drugs             80 (8.3%)     30 (6.0%)     31 (11.0%)    19 (10.2%)    0.029
          Alcohol consumption \<19 g/day                869 (89.9%)   459 (92.0%)   246 (87.5%)   164 (87.7%)   0.079
          No drinkers                                   614 (63.5%)   326 (65.3%)   168 (59.8%)   120 (64.2%)   0.297
          Smoking                                       275 (28.4%)   116 (23.2%)   85 (30.2%)    74 (39.6%)    \<0.001
          Physical activities                           280 (29.0%)   141 (28.3%)   86 (30.6%)    53 (28.3%)    0.769
          Eating fast                                   366 (37.8%)   162 (32.5%)   116 (41.3%)   88 (47.1%)    0.001
          Eating before sleeping                        327 (33.8%)   150 (30.1%)   100 (35.6%)   77 (41.2%)    0.018

Compared using the Kruskal--Wallis test. Other comparisons made using the χ^2^ test.

SI conversion factor: To convert cholesterol to millimoles per liter, multiply by 0.0259.

FLI, fatty liver index; DBP, diastolic blood pressure; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol SBP, systolic blood pressure.

Table[4](#tbl4){ref-type="table"} compares the proportions, unadjusted odds ratios (ORs) and 95% CIs for diabetes, and the results of multiple logistic regression analyses according to FLI by sex. During the study period, progression of diabetes was seen in 65 men (11.5%) and 24 women (6.0%). The incidence of DM was significantly different in both sexes (*P* = 0.008, *P* \< 0.001). Participants with intermediate FLIs and those with NAFLD had significantly higher risks of DM, in both men (OR 2.35, 2.88; 95% CI 1.18--4.70, 1.42--5.83; *P* for trend 0.003) and women (OR 2.95, 10.86; 95% CI 1.07--8.19, 3.83--30.82; *P* for trend \<0.001). Logistic regression analyses showed that those with intermediate FLIs and those with NAFLD had significantly higher risks of developing DM; this was the case in both men (OR 2.28, 2.68; 95% CI 1.12--4.63, 1.29--5.56; *P* for trend 0.023) and women (OR 3.01, 10.35; 95% CI 1.03--8.78, 3.22--33.31; *P* for trend \<0.001).

###### 

Comparison of odds ratios and 95% confidence intervals for diabetes, and results of multiple logistic regression analyses, according to fatty liver index by sex

                                            FLI         *P*-value                                     
  ----------------------------------------- ----------- --------------------- ----------------------- -----------------------------------------
  Men                                                                                                 
   No. DM cases                             13 (6.2%)   27 (13.5%)            25 (16.0%)              0.008[†](#tf4-1){ref-type="table-fn"}
    No. patients with HbA1c \> 6.4          13 (6.2%)   26 (13.0%)            21 (13.5%)              
    No. patients taking treatments for DM   0 (0.0%)    4 (2.0%)              8 (5.1%)                
   Unadjusted odds ratio                    Reference   2.35 \[1.18--4.70\]   2.88 \[1.42--5.83\]     0.003
   Adjusted odds ratio                      Reference   2.28 \[1.12--4.63\]   2.68 \[1.29--5.56\]     0.023
  Women                                                                                               
   No. DM patients                          9 (0.3%)    7 (8.6%)              8 (25.8%)               \<0.001[†](#tf4-1){ref-type="table-fn"}
    No. patients with HbA1c \>6.4           6 (0.2%)    7 (8.6%)              7 (22.6%)               
    No. patients taking treatments for DM   3 (0.1%)    1 (1.2%)              1 (3.2%)                
   Unadjusted odds ratio                    Reference   2.95 \[1.07--8.19\]   10.86 \[3.83--30.82\]   \<0.001
   Adjusted odds ratio                      Reference   3.01 \[1.03--8.78\]   10.35 \[3.22--33.31\]   \<0.001

Compared using the χ^2^-test. Other comparisons made using the trend test.

Hosmer--Lemeshow goodness of fit: *P = *0.714 in men, and *P *= 0.651 in women, respectively.

Adjusted by age, smoking habits, physical activities, eating habits before sleeping,eating fast, hypertension, hypercholesterolemia and prefecture.

DM, diabetes mellitu; FLI, fatty liver index.

Discussion
==========

The present study showed that NAFLD assessed by FLI and questionnaires is an independent risk factor for DM among insurance beneficiaries with prediabetes undergoing specific health check-ups. The results are consistent with previous studies, which reported that NAFLD is a risk factor for prediabetes or type 2 DM among subjects without DM or prediabetes[@b6],[@b10],[@b14]. Above all, the present results are similar to those of a previous study that used the FLI, in terms of risk for DM. In the previous study, risk was especially high among women with NAFLD, although adjusted ORs were estimated at remarkably high values: OR 4.71, 95% CI 1.68--7.28 in men and OR 22.77, 95% CI 6.78--76.44 in women[@b14].

NAFLD could progress to non-alcoholic steatohepatitis (NASH) and liver cirrhosis. Therefore, the current study\'s results also suggest that it would be advantageous for insurers to carefully monitor for early detection of NAFLD in insurance beneficiaries with prediabetes, and to intervene earlier in both diseases. For example, weight loss is an effective intervention to prevent DM among patients with prediabetes[@b23]--[@b26], whereas a recent randomized controlled trial reported that community-based lifestyle modifications targeting BMI 23 kg/m^2^ were effective in reducing and normalizing liver fat in NAFLD patients[@b27]. Furthermore, although thiazolidinediones were only used for type 2 DM in Japan, they reduced insulin resistance to prevent DM among patients with IGT or IFG[@b28],[@b29], and decreased AST, ALT and hepatic fat content among non-alcoholic steatohepatitis patients with IGT or type 2 DM[@b30],[@b31]. In addition to issues around application to prediabetes, a recent meta-analysis investigating ethnic differences in insulin sensitivity and response reported that insulin sensitivity of East Asians with impaired glucose regulation was significantly higher than that of Africans[@b32]. These interventions would be effective if aimed at insurance beneficiaries with NAFLD and prediabetes.

There were several limitations to the present study. First, we used FLI as a surrogate marker for NAFLD, because specific health check-ups did not include scanning tests, such as ultrasounds or magnetic resonance spectroscopy. Second, as each component of the FLI is a risk factor for diabetes by itself, it would be controversial if NAFLD was an independent predictor for DM and if cut-off points of the FLI were appropriate. Third, we used a self-administered questionnaire to define DM. Therefore, information bias could exist. Furthermore, it is also unclear whether the findings could be applied to other populations as well as Japanese. Finally, as the present study did not obtain fasting plasma glucose and a 2-h oral glucose tolerance test, the prevalence of DM would be underestimated.

However, the FLI has also validated in Korean populations[@b33], while it was developed and its validity has been examined in European populations[@b11],[@b34]. It was required to monitor those with prediabetes for identification and quantification[@b17]; nevertheless, just nine patients with prediabetes have received specific health guidance at FY2008.Therefore, it is expected that insurers would develop a disease management program for insurance beneficiaries who had an especially higher risk for DM. Because of the increasing prevalence of NAFLD, a simpler surrogate measure would be important to prevent NAFLD, and its adverse hepatic and extrahepatic consequences. As diagnosing NAFLD by using scanning tests requires radiological equipment and experts, the utilization of simpler and more cost-effective screening methods for NAFLD is necessary to identify people who might have NAFLD at annual health check-ups. Also, because it could be calculated by measures commonly used during specific health check-ups, the FLI and questionnaires could be used as surrogate measures for NAFLD during these check-ups.

In conclusion, among insurance beneficiaries with prediabetes, those with NAFLD had a significantly higher risk of DM than those without NAFLD. The FLI might be useful for detecting those who had an especially higher risk for DM, and for developing more effective guidance for delivering healthcare services in Japan.
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